Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

<p><strong>Aims</strong> Statins reduce LDL cholesterol (LDL-C) and the risk of vascular events, but it remains uncertain whether there is clinically relevant genetic variation in their efficacy. This study of 18 705 individuals aims to identify genetic variants related to the lipi...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hopewell, J, Parish, S, Offer, A, Link, E, Clarke, R, Lathrop, M, Armitage, J, Collins, R
Format:	Journal article
Idioma:	English
Publicat:	Oxford University Press 2013

Ítems similars

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
per: Hopewell, J, et al.
Publicat: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
per: Hopewell, J, et al.
Publicat: (2011)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
per: Hopewell, J, et al.
Publicat: (2010)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
per: Hopewell, JC, et al.
Publicat: (2020)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
per: Hopewell, J, et al.
Publicat: (2011)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
per: Parish, S, et al.
Publicat: (2012)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
per: Collins, R, et al.
Publicat: (2003)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
per: Hopewell, J, et al.
Publicat: (2011)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
per: Hopewell, J, et al.
Publicat: (2012)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
per: Hopewell, J, et al.
Publicat: (2009)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
per: Bulbulia, R, et al.
Publicat: (2008)

Safety of long-term simvastatin discontinuation Reply
per: Bulbulia, R, et al.
Publicat: (2012)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
per: Collins, R, et al.
Publicat: (2004)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
per: Armitage, J, et al.
Publicat: (2009)

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
per: Mihaylova, B, et al.
Publicat: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
per: Mihaylova, B, et al.
Publicat: (2006)

Heart Protection Study - Reply
per: Collins, R, et al.
Publicat: (2003)

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease
per: Hopewell, J, et al.
Publicat: (2012)

C-reactive protein in the Heart Protection Study - Authors' reply
per: Emberson, J, et al.
Publicat: (2011)

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
per: Keech, A, et al.
Publicat: (1996)

MRC/BHF Heart Protection Study - Reply
per: Collins, R, et al.
Publicat: (2002)

New analyses of Heart Protection Study - Reply
per: Collins, R, et al.
Publicat: (2004)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
per: Mihaylova, B, et al.
Publicat: (2005)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
per: Bulbulia, R, et al.
Publicat: (2011)

C-reactive protein in the Heart Protection Study Reply
per: Emberson, J, et al.
Publicat: (2011)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
per: Collins, R, et al.
Publicat: (2003)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
per: Armitage, J, et al.
Publicat: (2010)

Economic evaluation of the Heart Protection Study
per: Briggs, A, et al.
Publicat: (2003)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
per: Link, E, et al.
Publicat: (2008)

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
per: Hanson Mary E, et al.
Publicat: (2010-07-01)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
per: Collins, R, et al.
Publicat: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
per: Emberson, J, et al.
Publicat: (2005)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
per: Alexander, W, et al.
Publicat: (2011)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
per: Bulbulia, R, et al.
Publicat: (2007)

Common Genetic Variants Associated With Higher Lp(a) Concentrations and Increased Risk of Coronary Heart Disease
per: Clarke, R, et al.
Publicat: (2009)

AGW 705 - ADVANCED MARKETING SEMINAR APRIL 08.
per: PPP, Pusat Pengajian Pengurusan
Publicat: (2008)

Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
per: Parish, S, et al.
Publicat: (2018)

The MRC/BHF Heart Protection Study: preliminary results.
per: Collins, R, et al.
Publicat: (2002)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
per: Emberson, J, et al.
Publicat: (2005)

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
per: Hopewell, J, et al.
Publicat: (2014)